Hypertriglyceridemic Acute Pancreatitis
Conditions
Interventions
Experimental group:Standard treatment + fecal microbiota transplantation
Control group:Standard treatment
Sponsors
Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of hypertriglyceridemic acute pancreatitis with SIRS; 2. The first FMT can be completed within 6 hours after enrollment and there is no organ failure at the time of administration; 3. Age 18 to 65 years old, male or female; 4. Patients or their families agree to participate in the study and sign the informed consent form, and the compliance and tolerability are good.
Exclusion criteria
Exclusion criteria: 1. Contraindications for FMT: severe immunodeficiency or malignant tumors, active gastrointestinal bleeding and perforation, toxic megacolon, severe intestinal obstruction, active systemic infection, severe coagulation disorders; 2. Use of antibiotics, probiotics, or fecal transplantation within the past month; 3. Severe intestinal diseases (active Crohn's disease, active ulcerative colitis, short bowel syndrome, active intestinal fistula); 4. Severe underlying diseases (severe heart, lung, liver, or kidney dysfunction, as well as patients with impaired consciousness or coma); 5. Mental disorders, cognitive impairment, or inability to comply and follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in improvement rate of inflammatory markers (C-reactive protein) between the experimental and control groups during the baseline period and post-treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events associated with faecal microbiota transplantation during hospitalisation;Inpatient surgical/endoscopic intervention rate, antibiotic utilisation rate, organ support rate;The incidence of persistent organ failure during hospitalisation;Serum metabolite alterations, gut microbiota changes;ICU occupancy rate during hospitalisation, length of stay, total treatment costs;Incidence of systemic complications during hospitalisation;90-day recurrence rate of pancreatitis and all-cause mortality;Incidence of local complications within 90 days;Laboratory parameters (rate of reduction in serum triglyceride levels, time to achieve target levels; levels of other inflammatory markers (procalcitonin, interleukin-6, erythrocyte sedimentation rate;AP-related scores (BISAP score, modified CT severity index, SOFA score, AGI grading score); | — |
Countries
China
Contacts
Public ContactHuihong Zhai
Xuanwu Hospital, Capital Medical University
Outcome results
None listed